Lexicon Pharmaceuticals (LXRX) Competitors

Celldex Therapeutics (NASDAQ:CLDX) and Lexicon Pharmaceuticals (NASDAQ:LXRX) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, institutional ownership, risk, dividends, earnings, profitability, media sentiment and analyst recommendations.

Does the media favor CLDX or LXRX?

In the previous week, Lexicon Pharmaceuticals had 1 more articles in the media than Celldex Therapeutics. MarketBeat recorded 2 mentions for Lexicon Pharmaceuticals and 1 mentions for Celldex Therapeutics. Celldex Therapeutics' average media sentiment score of 1.16 beat Lexicon Pharmaceuticals' score of 0.59 indicating that Celldex Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Celldex Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Lexicon Pharmaceuticals	1 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Do analysts rate CLDX or LXRX?

Celldex Therapeutics currently has a consensus price target of $50.11, indicating a potential upside of 138.85%. Lexicon Pharmaceuticals has a consensus price target of $3.67, indicating a potential upside of 320.10%. Given Lexicon Pharmaceuticals' higher possible upside, analysts clearly believe Lexicon Pharmaceuticals is more favorable than Celldex Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Celldex Therapeutics	0 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.89
Lexicon Pharmaceuticals	0 Sell rating(s)	3 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.40

Which has preferable valuation and earnings, CLDX or LXRX?

Celldex Therapeutics has higher earnings, but lower revenue than Lexicon Pharmaceuticals. Celldex Therapeutics is trading at a lower price-to-earnings ratio than Lexicon Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Celldex Therapeutics	$7.02M	198.38	-$157.86M	-$2.70	-7.77
Lexicon Pharmaceuticals	$31.08M	10.15	-$200.40M	-$0.51	-1.71

Is CLDX or LXRX more profitable?

Lexicon Pharmaceuticals has a net margin of -568.04% compared to Celldex Therapeutics' net margin of -2,366.07%. Celldex Therapeutics' return on equity of -23.46% beat Lexicon Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Celldex Therapeutics	-2,366.07%	-23.46%	-22.35%
Lexicon Pharmaceuticals	-568.04%	-103.16%	-54.95%

Do insiders and institutionals have more ownership in CLDX or LXRX?

74.7% of Lexicon Pharmaceuticals shares are owned by institutional investors. 4.4% of Celldex Therapeutics shares are owned by company insiders. Comparatively, 13.9% of Lexicon Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Which has more risk and volatility, CLDX or LXRX?

Celldex Therapeutics has a beta of 1.13, indicating that its share price is 13% more volatile than the S&P 500. Comparatively, Lexicon Pharmaceuticals has a beta of 1.13, indicating that its share price is 13% more volatile than the S&P 500.

Summary

Celldex Therapeutics and Lexicon Pharmaceuticals tied by winning 8 of the 16 factors compared between the two stocks.